Vimarsana
Biggest News Aggregation in the World

Page 12 - Plenary News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Plenary. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Plenary Today - Breaking & Trending Today

Merus N.V.: Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Upda - Vimarsana News

Merus N.V.: Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Upda

- Robust 36% overall response rate (ORR) in 42 evaluable patients - 6 months median duration of response with 17 patients still on treatment as of Nov. 28, 2022 data cutoff - End-of-Phase meeting

NUP MPs return as Ssegirinya attends first plenary - Vimarsana News

NUP MPs return as Ssegirinya attends first plenary

The legislators were surprised that they had returned at a time when several changes had been effected at the 11th Parliament

Our intention is to get South Africa off the grey list, says Ramaphosa - Vimarsana News

Our intention is to get South Africa off the grey list, says Ramaphosa

The cabinet has established an interdepartmental committee to ensure South Africa continues to address issues raised by the Financial Action Task Force, President Cyril Ramaphosa said on Thursday.

USR MPs protest in Senate plenary hall foyer: Cut special pensions - Vimarsana News

USR MPs protest in Senate plenary hall foyer: Cut special pensions

Save Romania Union (USR) MPs protested Wednesday in the foyer of the Senate plenary hall against the draft law on special pensions.They displayed…

Agenus' Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer - Vimarsana News

Agenus' Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer

Data presented at plenary session of Society of Gynecologic Oncology Meeting  Patients treated suffered from platinum resistant/refractory ovarian cancer Previous PD-1/CTLA-4... | March 27, 2023